SAMHD1 Antibody, Unconjugated, Rabbit, Polyclonal

Produktübersicht

• Artikelname: SAMHD1 Antibody, Unconjugated, Rabbit, Polyclonal
• Artikelnummer: PRS-8007
• Hersteller Artikelnummer: 8007
• Alternativnummer: PRS-8007-0.02,PRS-8007-0.1
• Hersteller: ProSci
• Wirt: Rabbit
• Kategorie: Antikörper
• Applikation: ELISA, IF, IHC, WB
• Spezies Reaktivität: Human, Mouse
• Immunogen: Anti-SAMHD1 antibody (8007) was raised against a peptide corresponding to 18 amino acids near the carboxy terminus of human SAMHD1.
• Konjugation: Unconjugated
• Alternative Synonym: SAM domain and HD domain 1, DCIP, CHBL2, HDDC1, MOP-5, SBBI88

Produkteigenschaften

• Klonalität: Polyclonal
• Konzentration: 1 mg/mL
• Molekulargewicht: Predicted: 72kDObserved: 72 kD
• NCBI: 25939
• UniProt: Q9Y3Z3
• Puffer: SAMHD1 antibody is supplied in PBS containing 0.02% sodium azide.
• Formulierung: Liquid

Anwendungsbeschreibung

• Application Verdünnung: Optimal dilutions for each application to be determined by the researcher.
• Anwendungsbeschreibung: WB: 1 µg/mL, IHC: 5 µg/mL, IF: 20 µg/mL.Antibody validated: Western Blot, Immunohistochemistry, Immunofluorescence in human samples. All other applications and species not yet tested.

Bilder

Figure 1 Western Blot Validation in Human Daudi Cell LinesLoading: 15 &956,g of lysates per lane.Antibodies: SAMHD1 8007, 1 &956,g/mL, in (A: the absence and B: the presence of blocking peptide), (1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 4 Immunofluorescence Validation of SAMHD1 in Human Daudi cellsImmunofluorescent analysis of 4% paraformaldehyde-fixed Human Daudi Cells labeling SAMHD1 with 8007 at 20 &956,g/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Figure 3 Immunohistochemistry Validation of SAMHD1 in Human Brain Tissue Immunohistochemical analysis of paraffin-embedded Human Brain Tissue using anti- SAMHD1 antibody (8007) at 5 &956,g/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 &730,C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Figure 2 Overexpression Validation in 293T Transfected CellsLoading: 15 &956,g of lysates per lane.Antibodies: SAMHD1 8007 (0.1 &956,g/mL), (1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.293 cells were transfected with (1) wild-type SAMHD1 or (2) SAMHD1 (mutation T592A).

Figure 5 KO Validation of SAMHD1 in xenograft mice (Kodigepalli et al., 2018) THP-1 control and SAMHD1 KO (THP-1/KO) cells were injected into NSG (non-obese diabetic/severe combinedimmune deficient-gamma) mice. Protein expression levels of SAMHD1 were examined by Western blot with anti-SAMHD1 antibodies (8007) and SAMHD1 was not detected in THP-1/KO cells.

Figure 6 Overexpression Validation of SAMHD1 in CD4+ T-cells from a healthy donor and transformed CD4+ T-cell lines (Kohnken et al., 2017) MT1, MT2, SLB-1, and C8166 were from leukemia patients and HH, HuT78, and HuT102 were from cutaneous T-cell lymphoma (CTCL) patients. SAMHD1 protein expression detected by anti-SAMHD1 antibodies (8007) was significantly increased in normal CD4+ T-cells as compared to leukemia- and CTCL- derived CD4+ T-cell lines. This blot is representative from four independent experiments with four healthy donors.

Figure 7 Overexpression of SAMHD1 in CD4+ T-cells from Healthy Donors and Sezary Syndrome (SS) patients(Kohnken et al., 2017)SAMHD1 protein expression detected by anti-SAMHD1 antibodies (8007) was significantly reduced in CD+ T-cells from 15 SS patients as compared to those from 7 healthy donors.

Figure 8 Regulated Expression Validation of SAMHD1 in CD4+ T-cells from a healthy donor (Kohnken et al., 2017)SAMHD1 protein expression detected by anti-SAMHD1 antibodies (8007) was significantly decreased by about 40% relative to control cells at 48hr post-nucleofection with miR-181b.

Figure 9 Regulated Expression Validation of SAMHD1 in MT2 CD4+ T-cells from leukemia patients(Kohnken et al., 2017)SAMHD1 protein expression detected by anti-SAMHD1 antibodies (8007) was significantly increased by 5-fold at 48hr post-nucleofection with miR-181family inhibitor treatment.